NCT04863131View on ClinicalTrials.gov

Safety and Immunogenicity of EXG-5003

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

January 24, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

EXG-5003

COVID-19 self-replicating mRNA vaccine

BIOLOGICAL

Placebo

placebo solution

Trial Locations (1)

Unknown

Fujita Health University Hospital, Toyoake

Sponsors
All Listed Sponsors
collaborator

Elixirgen Therapeutics, Inc.

INDUSTRY

lead

Fujita Health University

OTHER

NCT04863131 - Safety and Immunogenicity of EXG-5003 | Biotech Hunter | Biotech Hunter